Carlyle, Abingworth again testing Launch model with Pathalys’ kidney disease asset
Leading $150M round, PE-backed venture firm will draw on clinical expertise of organization set up to advise on late-stage trials
Carlyle’s latest biotech deal since acquiring Abingworth last year is Wednesday’s agreement to back kidney disease company Pathalys as it prepares for Phase III trials of upacicalcet to treat secondary hyperparathyroidism in patients on dialysis, with assistance from the firm’s Launch entity.
Abingworth, now a unit of Carlyle Group Inc. (NYSE:CG), led Pathalys Pharma Inc.’s new $150 million round alongside Carlyle, OrbiMed Advisors and prior investors Catalys Pacific and DaVita Venture Group. Pathalys believes it is now fully funded to complete two Phase III studies of upacicalcet (PLS240), a small molecule calcimimetic approved in Japan as Upasita to treat secondary hyperparathyroidism in end-stage kidney disease patients on dialysis...
BCIQ Company Profiles